A bill to amend the Pharmaceutical and Medical Devices (PMD) Law is expected to be submitted to the ordinary session of the Diet this year, which was convened on January 17 for a 150-day run. The proposed amendment is for…
REGULATORY
Diet Submission of Clinical Research Bill Expected for Next Year: Panel Member
A bill on the legal regulation of clinical research is expected to be tabled to the next ordinary Diet session, which will convene in January for a 150-day run, a member of a health ministry panel said on December 12.…
To read the full story
Related Article
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
- Clinical Research Bill Won’t Be Enacted in Current Diet Session: LDP Health Panel Chief
March 30, 2016
- Difficult to Enact Clinical Research Bill in Current Diet Session: LDP Health Panel Chief
March 9, 2016
- Panel Reveals Final Report Calling for Legal Regulations for Clinical Research
December 12, 2014
- Panel Gives Green Light to Draft Report Calling for Legal Regulations for Clinical Research
November 27, 2014
REGULATORY
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- Japan Panel Agrees to Vaccinate Children under Free COVID-19 Inoculation Program
January 27, 2022
- Up to 3 Refills Permitted per Prescription, No Refilling for Drugs with Dosage Restrictions: Chuikyo
January 27, 2022
- Drug Pricing Rules to Be Applied to BMS’ CAR-T Therapy Abecma: Chuikyo
January 27, 2022
- PMDA to Place Top Priority on Safety Measures under Proposed Emergency Approval System: Chief Executive
January 25, 2022
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…
Japan’s all-important reimbursement policy panel on December 22 approved an outline of the next drug pricing reform scheduled for April 2022, which embraces plans to reward innovative new indications and introduce a grace period for so-called “spillover” re-pricing.The reform outline…
Remember what it was like back in March, when we all started working from home? There was a distinct change in the air - a sense of freedom and excitement about the novelty of being able to work from home.…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…